Our results demonstrate that SGLT2 inhibitors confer robust protective effects across both infectious (pneumonia, bronchitis) and non-infectious (COPD, respiratory failure) respiratory outcomes. The gene discussed is SLC5A2; the disease is bronchial disorder.